| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-09 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
Trial sites expanded: 13 -> 25 locations |
| 2026-06-05 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-05 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
Trial sites reduced: 25 -> 13 locations |
| 2026-05-28 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
date change Completion pushed: 2032-01-26 -> 2032-04-05 |
| 2026-05-15 | NCT05739942 Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent… |
Trial sites reduced: 23 -> 16 locations |
| 2026-05-15 | NCT05739942 Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent… |
date change Primary completion pushed: 2026-12-10 -> 2028-11-08 |
| 2026-05-15 | NCT05739942 Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent… |
date change Completion moved earlier: 2032-07-01 -> 2028-11-08 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 1/2 | |||
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With… | Breast Cancer | Recruiting |
| Phase 1 | |||
| NCT05870579 | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… | Breast Cancer | Recruiting |
| NCT05739942 | Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent… | Newly Diagnosed and Recurrent Glioblastoma | Active, Not Recruiting |
| NCT06379217 | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted… | Metastatic Neuroendocrine Prostate Cancer | Active, Not Recruiting |